Extrait

To assess if a switch from MMF to myfortic® results in improved GI- and/or health-related quality of life outcomes, and to determine the proportion of liver transplant recipients who are experiencing any GI complaints under MMF-based immunosuppressive treatment.

Critère d'inclusion

• patients who have received a liver transplant treated with mycophenolic acid

Liens

• ictrp
• euctr